|Articles|October 24, 2017
PAREXEL and Microsoft Form Alliance Aimed at Accelerating the Pace of Drug Development
Advertisement
PAREXEL International Corp. and Microsoft Corp. have announced a technology development alliance that plans to help the industry accelerate drug development and provide faster therapies to patients. By combing each companies' expertise and capabilities, this new collbaoration will drive innovation across the life sciences industry.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
3
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
4
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
5